Relationship between ROS1 gene and efficiency of pemetrexed combined with platinum chemotherapy in patients with stage Ⅳ lung adenocarcinoma#br#
TAO Jie1 XUE Shuping2 MA Xiaomei3▲
1.Ward One, Department of Pulmonary Medicine, Tumor Hospital Affiliated to Xinjiang Medical University, Xinjiang Uygur Autonomous Regin, Urumqi 830011, China;
2.the Second Daytime Ward, Tumor Hospital Affiliated to Xinjiang Medical University, Xinjiang Uygur Autonomous Regin, Urumqi 830011, China;
3.Department of Pathology, Tumor Hospital Affiliated to Xinjiang Medical University, Xinjiang Uygur Autonomous Regin, Urumqi 830011, China
Abstract：Objective To investigate the relationship between ROS1 gene and efficiency of pemetrexed combined with platinum chemotherapy in patients with stage Ⅳ lung adenocarcinoma. Methods A total of 384 patients with stage Ⅳ lung adenocarcinoma treated in the Tumor Hospital Affiliated to Xinjiang Medical University from June 2015 to September 2018 were collected. According to ROS1 gene status, patients were divided into ROS1 positive group (32 cases) and ROS1 negative group (352 cases). All patients underwent ROS1 gene detection and received Pemetrexed combined with platinum chemotherapy. Relationships between objetive reposnse rate (ORR), disease control rate (DCR), progression free survival (PFS) and ROS1 gene status were analyzed. Results The ORR, DCR of ROS1 positive group were higher than ROS1 negative group (P ＜ 0.05). The survival rate of patients in ROS1 positive group was higher than that in ROS1 negative group (P ＜ 0.05). ROS1 gene was an influencing factor of death (HR = 0.590, 95%CI:0.403-0.863, P ＜ 0.05). Conclusion The first-line treatment of ROS1 positive patients with stage Ⅳ lung adenocarcinoma with Pemetrexed combined with platinum chemotherapy is better, and the time without disease progression is prolonged.
陶洁1 薛淑萍2 马晓梅3▲. Ⅳ期肺腺癌患者ROS1基因状态与使用培美曲塞联合铂类方案化疗效果的关系[J]. 中国医药导报, 2022, 19(11): 111-114,142.
TAO Jie1 XUE Shuping2 MA Xiaomei3▲. Relationship between ROS1 gene and efficiency of pemetrexed combined with platinum chemotherapy in patients with stage Ⅳ lung adenocarcinoma#br#. 中国医药导报, 2022, 19(11): 111-114,142.
[1] Sholl LM，Sun H，Butaney M，et al. ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas [J]. Am J Surg Pathol，2013，37（9）：1441-1449.
[2] Lu S，Mok T，Lu Y，et al. Phase 3 study of first-line Crizotinib vs Pemetrexed- Cisplatin/Carboplatin in east Asian patients with ALK+ advanced non-squamous non-small cell lung cancer（NSCLC） [J]. J Clin Oncol，2016， 34（Suppl）：9058.
[3] Yao Y，Peng M，Shen Q，et al. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples [J]. Thorac Cancer，2019，10（2）：193-202.
[4] Song Z，Su H，Zhang Y. Patients with ROS1 rearrangement-positive non-small-cell lung Cancer benefit from pemetrexed－based chemotherapy [J]. Cancer Med，2016，5（10）：2688-2693.
[5] Amin MB，Edge S，Greene F，et al. AJCC Cancer Staging Manual（8th edition）[M]. Springer International Publishing：American Joint Commission on Cancer，2017.
[6] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours： revised RECIST guideline （version 1.1） [J]. Eur J Cancer，2009，45（2）：228-247.
[7] Shaw AT，Riely GJ，Bang YJ，et al. Crizotinib in ROS1- rearranged advanced non-small cell lung cancer （NSCLC）： updated results，including overall survival，from PROFILE 1001 [J]. Ann Oncol，2019，30（7）：1121-1126.
[8] Shen L，Qiang T，Li ZM，et al. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer [J]. Cancer Med，2020，9（10）：3310-3318.
[9] Wu YL，Yang JC，Kim DW，et al. Phase Ⅱ study of crizotinib in East Asian patients with ROS1-positive advanced non-small cell lung cancer [J]. J Clin Oncol，2018，36（14）：1405-1411.
[10] Zhang YC，Zhang XY，Zhang RG，et al. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer：a large multicenter retrospective study [J]. BMC Med，2021，19（1）：206.
[11] Choudhury NJ，Schneider JL，Patil T，et al. Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers [J]. JTO Clin Res Rep，2021，2（7）：100187.
[12] Chu P，Antoniou M，Bhutani M K，et al. Matching-adjusted indirect comparison：entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer [J]. J Comp Eff Res，2020，9（12）：861-876.
[13] Kim HR，Lim SM，Kim HJ，et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma [J]. Ann Oncol，2013，24（9）：2364-2370.
[14] Chen YF，Hsieh MS，Wu SG，et al. Efficacy of pemetrexed-based hemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in atients harboring other driver mutations in East Asian populations [J]. Thorac Oncol，2016，11（7）：1140-1152.
[15] D’Angelo A，Sobhani N，Chapman R，et al. Focus on ROS1-Positive Non-Small Cell Lung Cancer （NSCLC）： Crizotinib，Resistance Mechanisms and the Newer Generation of Targeted Therapies [J]. Cancers （Basel），2020， 12（11）：3293.
[16] Pan Y，Zhang Y，Li Y，et al. ALK，ROS1 and RET fusions in 1139 lung adenocarcinomas： a comprehensive study of com-mon and fusion attern-specific clinicopatnologic，histologic and cytologic features [J]. Lung Cancer，2014，84（2）：121-126.
[17] Morris TA，Khoo C，Solomon BJ. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer： Crizotinib and Newer Generation Tyrosine Kinase Inhibitors [J]. Drugs，2019，79（12）：1277-1286.
[18] Catelain C，Pailler E，Oulhen M，et al. Detection of Gene Rearrangements in Circulating Tumor Cells： Examples of ALK-，ROS1-，RET-Rearrangements in Non-Small-Cell Lung Cancer and ERG-Rearrangements in Prostate Cancer [J]. Adv Exp Med Biol，2017，994：169-179.
[19] Patil T，Smith DE，Bunn PA. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib [J]. J Thorac Oncol，2018，13（11）：1717-1726.
[20] Boyle TA，Masago K，Ellison KE，et al. ROS1 immunohistochemistry among major genotypes of none small cell lung cancer [J]. Clin Lung Cancer，2015，16（2）：106-111.
[21] Choi M，Kim HT，Han JY，et al. Phase Ⅱ Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer [J]. Cancer Res Treat，2021，53（1）：87-92.
[22] Cao B，Wei P，Liu Z，et al. Detection of lung adenocarcinoma with ROS1 rearrangement by IHC，FISH，and RT-PCR and analysis of its clinicopathologic features [J]. Onco Targets Therapy，2016，31（9）：131-138.
[23] Monica V，Iacono ML，Bracco E，et al. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines [J]. Oncotarget，2016，7（47）：76577-76589.
[24] Siddiqui MA，Gollavilli PN，Ramesh V，et al. Thymidylate synthase drives the phenotypes of epithelial-tomesenchymal transition in non-small cell lung cancer [J]. Br J Cancer，2021，124（1）：281-289.
京公网安备 11010502046598号